Trial | NCT03704740  Report issue

Title

Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months
A Multinational, Comparative Phase III Clinical Trial to Assess the Efficacy (Immunogenicity) and Safety of NBP607-QIV (0.5 mL) (Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine) in Children Aged 6 to 35 Months

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    676
This study assesses immunogenicity and safety of NBP607-QIV to Agrippal which are indicated for active immunization for the prevention of influenza disease. Total of 675 subjects or above (450 subjects for NBP607-QIV arm and 225 subjects for Agrippal arm) of 6 to 35 months of age are enrolled, and each subject is administered with single or two doses of vaccines depending on previous vaccination history.
This is a multi-national, multi-center, randomized, double blinded, parallel-group study to assess the immunogenicity and safety of NBP607-QIV compared to Agrippal which are indicated for active immunization for the the prevention of influenza disease. Total of 675 subjects or above (450 subjects for NBP607-QIV arm and 225 subjects for Agrippal arm) of 6 to 35 months of age are enrolled. Each subject is administered with single or two doses of vaccines depending on previous vaccination history, and randomly assigned in 2:1 ratio.

Stratified randomization for trial site and age strata is used to achieve the balance of treatment assignment.

Total of three or five visits are scheduled depeding on dosing schedule. For subjects assigned to single-dose vaccination schedule, blood sampling is conducted for immunogenicity assessment before and 4 weeks after single vaccination at Visit 1 and 3 respectively. Safety is monitored 3 days, 4 weeks after vaccination through Visit 2* and 3 (* telephone contact). For subjects assigned to two-dose vaccination schedule, blood sampling is conducted before first vaccination and 4 weeks after second vaccination at Visit 1 and Visit 5 respectively. Safety is monitored 3 days, 4 weeks after each vaccination through Visit 2*, 3, 4*, and 5 (* telephone contact)
Study Started
Oct 25
2018
Primary Completion
Jul 12
2019
Study Completion
Jul 12
2019
Last Update
May 11
2022

Biological NBP607-QIV

Purified inactivated influenza virus surface antigens of four strains (quadrivalent)

Biological Agrippal

Influenza virus surface antigens of three strains (trivalent)

NBP607-QIV Experimental

One or two doses of 0.5mL of NBP607-QIV by intramuscular injection

Agrippal Active Comparator

One or two doses of 0.25mL of Agrippal by intramuscular injection

Criteria 

Inclusion Criteria:

Children aged 6 to 35 months
Those who were normal gestational age at birth (for children aged 6 months to <1 year)
Those who have provided written informed consent to study participation and compliance with study instructions after being informed of and understand details of the study

Exclusion Criteria:

Those with any immunodeficiency disease or malignancy
Those with hypersensitivity to vaccination
Those who are contraindicated for intramuscular injection due to thrombocytopenia or other coagulopathy
Those with history of treatment with any of immunosuppressants or immunoregulators within 12 weeks prior to screening
Those with history of receiving blood product or treatment with immunoglobulin within 24 weeks prior to screening
Those with history of influenza vaccination within 24 weeks prior to screening
Those with any severe chronic conditions that interfere with study participation
No Results Posted